FGK
PHARMACOVIGILANCE

Anthony W. Fox B.Sc. | MBBS | M.Sc. | LLM |M.D. (Lond) | FRCP | DipPharmMed | DipFHI | CBiol

Managing Director, QPPV

Tony Fox is a pharmaceutical physician with more than 30 years experience in large pharma, small pharma and biotech, both as a senior employee (then Glaxo Inc., North Carolina; Procter and Gamble, Norwich NY) and as an independent consultant. He led clinical teams that obtained regulatory approval for Imitrex®, Amerge® and Ultiva®. He was also formerly President of EBD Group (Carlsbad, California and Munich, Germany). He holds qualifying degrees in medicine and law, and a research doctorate in drug-receptor pharmacology, all from the University of London (UK). He is a Fellow of the Royal College of Physicians, a Life Fellow of the Royal Society for the Encouragement of Arts, Manufactures and Commerce, and a Liveryman of the Worshipful Society of Apothecaries (with the Freedom of the City of London). His numerous publications span pharmacovigilance, clinical and non-clinical toxicology, experimental medicine, clinical pharmacology and other industry-related subjects.

From 1994 to 1997, Tony Fox was Vice-President for Drug Development and Regulatory Affairs at Cypros Pharmaceuticals in Carlsbad, California, where he led two drugs from IND to Phase III. Prior positions include Director of Cardiovascular and Anaesthesia clinical research at Glaxo, where he led the US sumatriptan group and chaired the international remifentanil project (1990-1994). Group Leader with Procter and Gamble (phase I and II clinical trials and medical affairs). Tony Fox obtained three degrees from the University of London: BSc major in pharmacology (first class honours, 1977), his medical degree (1980) and a doctorate in pharmacology (1988). He is a Fellow of the Faculty and holds the Diploma in Pharmaceutical Medicine (Royal Colleges of Physicians, UK). Tony Fox co-edited “Treating the Headache Patient” with Roger Cady, and was on the editorial team of the major textbook “Practice and Principles of Pharmaceutical Medicine” which is going into its third edition.